The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

http://academiccme.com/wp-content/uploads/2017/12/AD-Image_-Module-1-wpcf_400x400.jpg

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): .50 AMA PRA Category 1 Credit(s)™
Activity Dates: December 7, 2017 to December 6, 2018

 

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Barry W. Rovner, along with Dr. Richard S. Isaacson, course chair, will provide learners with an update regarding beta-amyloid and tau biomarkers and their role in Alzheimer’s disease (AD) pathology and progression. Recent guidelines and trial data relating to beta-amyloid and tau will be reviewed, and clinical relevance debated. Drs. Rovner and Isaacson will also discuss the diagnostic criteria for Alzheimer’s disease and intervention techniques for the various stages of disease. Upon completion of this educational activity, learners will be better equipped with best practices for managing beta amyloid and tau levels in practice to provide optimal care for patients with AD.

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

I. Discuss recent developments in the diagnosis of AD such as the role of beta-amyloid and tau biomarkers

II. Implement shared decision making with the patient and caregiver to develop individualized approach to diagnosis and treatment to improve the quality of life for patients with AD

Chair

Isaacson Head ShotRichard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

 

Faculty

Rovner Head ShotBarry W. Rovner, MD
Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Faculty Relationship Identified With:
Barry W. Rovner, MD Nothing to disclose.

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of .50 CNE contact hour(s).

Financial Support

This activity has been supported by an independent educational grant from Biogen.
BUTTON


Provided by AcademicCME-web